Clinical Trial

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 10, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-10-20; most recent amendment 2026-02-06.
Status change: Not Yet Recruiting → Recruiting 2023-10-30
Trial Details
NCT Number NCT05592015
Lead Sponsor Jonathan Brammer
Conditions T-Cell Large Granular Lymphocyte Leukemia
Enrollment 30 participants
Start Date 2023-05-03
Primary Completion 2026-07-31 (estimated)
Study Completion 2026-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-10